GLIDUM MF 2 500 ER (Glimepiride (2mg) + Metformin (500mg))

Glidum-MF 2-500 ER is a medication that combines two active ingredients: Metformin Hydrochloride in a prolonged-release form (500 mg) and Glimepiride (2 mg). This therapeutic combination is specifically designed to aid in the management of type 2 diabetes mellitus. Metformin enhances the body’s sensitivity to insulin and lowers the production of glucose by the liver, while Glimepiride promotes the secretion of insulin from the pancreatic beta cells. Together, these actions help regulate blood glucose levels effectively, thus diminishing the likelihood of complications associated with diabetes. The extended-release characteristic of this formulation allows for a gradual release of the active ingredients into the bloodstream, which can lead to improved adherence to the treatment regimen and overall effectiveness of diabetes management. It is essential for patients to closely monitor their blood sugar levels and engage in regular consultations with their healthcare provider to ensure that the treatment remains appropriate and effective. Unlike immediate-release versions, Glidum-MF 2-500 ER is designed for less frequent dosing, which can enhance patient convenience. However, as with any medication, it is crucial to follow the prescribed guidelines and report any unusual symptoms or concerns to a healthcare professional promptly. Use this medicine only under medical supervision. Follow the dose and schedule exactly as advised. Do not stop abruptly without guidance. Keep a record of any unusual symptoms and share them with your clinician. Combine therapy with appropriate lifestyle measures and routine monitoring as recommended.